For: | Lu GF, Tang FA, Zheng PY, Yang PC, Qi YM. Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B. World J Gastroenterol 2008; 14(10): 1617-1621 [PMID: 18330958 DOI: 10.3748/wjg.14.1617] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v14/i10/1617.htm |
Number | Citing Articles |
1 |
Sheikh Mohammad Fazle Akbar, Maumn Al-Mahtab, Yoichi Hiasa. Future aspects of therapy for hepatitis B virus infection: value of surrogate markers, innovative therapy, and global collaboration. Journal of Gastroenterology 2011; 46(6): 717 doi: 10.1007/s00535-011-0401-2
|
2 |
Ri‐Cheng Mao, You‐Kuan Yin, Yan‐Li Qin, Xiang‐Hui Wu, Xin‐Hua Weng, Ji‐Ming Zhang, Mengji Lu. Spontaneous HBeAg seroconversion and loss of hepatitis B virus DNA after acute flare due to development of drug resistant mutants during entecavir monotherapy. Hepatology Research 2009; 39(1): 14 doi: 10.1111/j.1872-034X.2008.00411.x
|
3 |
Gang Li, Xiaojia Xiong. MicroRNAs and hepatitis viruses. Frontiers of Medicine in China 2009; 3(3): 265 doi: 10.1007/s11684-009-0055-0
|
4 |
Hui Zhang, Jianchun Xian, Yang Li, Li Xiao, Lu Wang, Muhammad Zia-Ul-Haq. Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine 2022; 2022: 1 doi: 10.1155/2022/1889628
|
5 |
João Panão Costa, Armando de Carvalho, Artur Paiva, Olga Borges. Insights into Immune Exhaustion in Chronic Hepatitis B: A Review of Checkpoint Receptor Expression. Pharmaceuticals 2024; 17(7): 964 doi: 10.3390/ph17070964
|
6 |
Shihong Zhong, Tianling Zhang, Libo Tang, Yongyin Li. Cytokines and Chemokines in HBV Infection. Frontiers in Molecular Biosciences 2021; 8 doi: 10.3389/fmolb.2021.805625
|
7 |
Xiaoguo Zhang, Lu Liu, Meng Zhang, Shuchun Gao, Yizhen Du, Yong An, Shijun Chen. The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis. Annals of Hepatology 2015; 14(2): 150 doi: 10.1016/S1665-2681(19)30776-8
|
8 |
Lesley J. Scott, Gillian M. Keating. Entecavir. Drugs 2009; 69(8): 1003 doi: 10.2165/00003495-200969080-00005
|
9 |
Angelo Aquino, Grazia Graziani, Ornella Franzese, Salvatore P. Prete, Enzo Bonmassar, Laura Bonmassar, Stefania D'Atri. Exogenous Control of the Expression of Group I CD1 Molecules Competent for Presentation of Microbial Nonpeptide Antigens to Human T Lymphocytes. Clinical and Developmental Immunology 2011; 2011: 1 doi: 10.1155/2011/790460
|
10 |
Bingliang Lin, Calvin Q. Pan, Dongying Xie, Junqiang Xie, Shibin Xie, Xiaohong Zhang, Biao Wu, Chaoshuang Lin, Zhiliang Gao. Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B. Hepatology International 2013; 7(2): 460 doi: 10.1007/s12072-012-9415-y
|
11 |
Li Wang, Zhi Qiang Zou, Cheng Xia Liu, Xiang Zhong Liu. Immunotherapeutic interventions in chronic hepatitis B virus infection: A review. Journal of Immunological Methods 2014; 407: 1 doi: 10.1016/j.jim.2014.04.004
|
12 |
Si‐Qi Wang, Yue Shen, Jing Li, Yun Liu, Li‐Sha Cheng, Sheng‐Di Wu, Wei‐Min She, Wei Jiang. Entecavir‐induced interferon‐λ1 suppresses type 2 innate lymphoid cells in patients with hepatitis B virus‐related liver cirrhosis. Journal of Viral Hepatitis 2021; 28(5): 795 doi: 10.1111/jvh.13476
|